H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Allogene Therapeutics to $10 from $12 and keeps a Buy rating on the shares. The analyst removed second-line large B cell lymphoma revenue for cema-cel from forecasts following the company’s pipeline updates earlier this month.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene Therapeutics price target lowered to $17 from $18 at Truist
- Caribou Biosciences price target lowered to $21 from $23 at Truist
- Allogene moved to Not Rated on strategy shift at Goldman Sachs
- Carnival upgraded, PayPal downgraded: Wall Street’s top analyst calls
